Alteon to Present at the Rodman & Renshaw Techvest Healthcare Conference and the C.E. Unterberg Towbin Specialty Pharmaceutical
22 October 2004 - 12:00AM
PR Newswire (US)
Alteon to Present at the Rodman & Renshaw Techvest Healthcare
Conference and the C.E. Unterberg Towbin Specialty Pharmaceutical
Conference PARSIPPANY, N.J., Oct. 21 /PRNewswire-FirstCall/ --
Alteon Inc. (AMEX:ALT) announced today that it will participate in
two investor healthcare conferences next week: the Rodman &
Renshaw Techvest 6th Annual Healthcare Conference and the C.E.
Unterberg Towbin Specialty Pharmaceutical Conference. Kenneth I.
Moch, President and Chief Executive Officer, will present at the
Rodman & Renshaw conference, being held at the Waldorf=Astoria
in New York City, on Wednesday, October 27, 2004 at 9:00 a.m., ET.
He will present at the C.E. Unterberg Towbin conference, being held
at The Palace Hotel in New York City, on Thursday, October 28, 2004
at 2:20 p.m., ET. The Rodman & Renshaw presentation will be
webcast live and will be accessible in the Investor Relations
section of Alteon's website, http://www.alteon.com/, where it also
will be archived after the event. About Alteon Alteon is developing
several new classes of drugs that have shown the potential to
reverse or slow down diseases of aging and complications of
diabetes. These compounds have an impact on a fundamental
pathological process caused by the progressive formation of
protein-glucose complexes called Advanced Glycation End-products
(A.G.E.s). The formation and crosslinking of A.G.E.s lead to a loss
of flexibility and function in body tissues and organs and have
been shown to be a causative factor in many age- related diseases
and diabetic complications. Alteon has created a library of novel
classes of compounds targeting the A.G.E. Pathway. Alteon's lead
compound alagebrium chloride (formerly ALT-711), the only A.G.E.
Crosslink Breaker in advanced human testing, has demonstrated
safety and efficacy in several Phase 2 trials and is actively being
developed for systolic hypertension and heart failure. Over 1200
patients have been involved in alagebrium's human clinical trials
to date, of whom approximately 900 have received active compound.
Ongoing clinical trials include the phase 2b systolic hypertension
trial, SPECTRA (Systolic Pressure Efficacy and Safety Trial of
Alagebrium), and the phase 2a heart failure trial, PEDESTAL
(Patients with Impaired Ejection Fraction and Diastolic
Dysfunction: Efficacy and Safety Trial of ALagebrium), as well as a
third trial exploring mechanism of action in endothelial
dysfunction. For more detailed scientific information about
alagebrium and a copy of the full abstract, please visit the
scientific publications section of the Alteon website,
http://www.alteon.com/. Any statements contained in this press
release that relate to future plans, events or performance are
forward-looking statements that involve risks and uncertainties
including, but not limited to, those relating to technology and
product development (including the possibility that early clinical
trial results may not be predictive of results that will be
obtained in large-scale testing or that any clinical trials will
not demonstrate sufficient safety and efficacy to obtain requisite
approvals or will not result in marketable products), regulatory
approval processes, intellectual property rights and litigation,
competitive products, ability to obtain financing, and other risks
identified in Alteon's filings with the Securities and Exchange
Commission. The information contained in this press release is
accurate as of the date indicated. Actual results, events or
performance may differ materially. Alteon undertakes no obligation
to publicly release the result of any revision to these
forward-looking statements that may be made to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events. DATASOURCE: Alteon Inc. CONTACT: Susan M.
Pietropaolo, Director, Corporate Communications & Investor
Relations, Alteon Inc., +1-201-818-5537 Web site:
http://www.alteonpharma.com/ http://www.alteon.com/
Copyright
Ishares Diversified Alternatives Trust (AMEX:ALT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ishares Diversified Alternatives Trust (AMEX:ALT)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Ishares Diversified Alternatives Trust (American Stock Exchange): 0 recent articles
More Alteon , News Articles